Form 4: Akero Therapeutics Chief Technology Officer Acquires Shares and Stock Options

Akero Therapeutics' Chief Technology Officer, Scott A. Gangloff, acquired 24,300 restricted stock units and 73,700 stock options on December 16, 2024.

Summary

• Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics, acquired 24,300 restricted stock units (RSUs) and 73,700 stock options on December 16, 2024.
• The RSUs vest in eight equal semi-annual installments starting December 16, 2024, contingent on continuous service.
• The stock options vest in 48 equal monthly installments starting December 16, 2024, also contingent on continuous service.
• The exercise price of the stock options is $29.23.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for the company's alignment of interests. The vesting schedules suggest a long-term commitment from the executive.

Positives

• The acquisition of shares and options by a key executive like the Chief Technology Officer can be seen as a positive sign of confidence in the company's future.
• The vesting schedules for both the RSUs and stock options incentivize long-term commitment from the executive.

Risks

• The vesting of the RSUs and stock options is contingent on continuous service, which could be a risk if the executive were to leave the company before full vesting.

Future Outlook

The vesting of the RSUs and stock options is tied to the executive's continued service with the company, suggesting a focus on long-term performance and stability.

Industry Context

This type of equity-based compensation is common in the biotechnology industry to attract and retain key talent, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules tied to continued service are also common, ensuring that executives remain committed to the company's long-term goals.
• Companies like Gilead Sciences, Amgen, and Biogen also use similar compensation structures for their executives.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company.
• Employees may see this as a sign of the company's investment in its leadership.

Key Dates

Keywords

Akero Therapeutics, stock options, restricted stock units, insider trading, executive compensation, vesting, Chief Technology Officer, AKRO